InspireMD Announces the Issuance of Two United States Patents

InspireMD, Inc. (NYSE MKT:

) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that the United States Patent & Trademark Office has issued two new patents to the Company on September 15th, U.S. Patent No. 9,132,261 entitled "In Vivo Filter Assembly" and U.S. Patent No. 9,132,003 entitled "Optimized Drug Eluting Stent Assembly." The In Vivo Filter Assembly patent covers an assembly for filtering debris flow in a blood vessel. The Optimized Drug Stent Assembly patent covers a stent assembly with the Company's proprietary MicroNet™ technology that elutes a drug. InspireMD continues to maintain a focus on its intellectual property portfolio, expanding coverage for its proprietary MicroNet™ technology, CGuard™ Embolic Prevention System for the treatment of carotid artery disease, and MGuard™ for coronary applications, in addition to several pending applications directed to its neurovascular and peripheral vascular platforms. The issuance of these two patents provides further support for these pending therapies and applications. To-date, the Company's patent rights in the United States include 4 issued patents and 10 pending applications. Foreign patent rights include 13 issued patents focused in Israel, Canada, and China, and 16 pending patent applications.